2018
Women and opioids: something different is happening here
Mazure CM, Fiellin DA. Women and opioids: something different is happening here. The Lancet 2018, 392: 9-11. PMID: 30047402, DOI: 10.1016/s0140-6736(18)31203-0.Peer-Reviewed Original Research
2016
Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infectionIn the Clinic. Alcohol Use.
Edelman EJ, Fiellin DA. In the Clinic. Alcohol Use. Annals Of Internal Medicine 2016, 164: itc1-16. PMID: 26747315, DOI: 10.7326/aitc201601050.Books
2012
Previous Use of Alcohol, Cigarettes, and Marijuana and Subsequent Abuse of Prescription Opioids in Young Adults
Fiellin LE, Tetrault JM, Becker WC, Fiellin DA, Hoff RA. Previous Use of Alcohol, Cigarettes, and Marijuana and Subsequent Abuse of Prescription Opioids in Young Adults. Journal Of Adolescent Health 2012, 52: 158-163. PMID: 23332479, PMCID: PMC3552239, DOI: 10.1016/j.jadohealth.2012.06.010.Peer-Reviewed Original ResearchConceptsPrescription opioidsPrevious marijuana usePrevious substance usePrevious alcoholMarijuana useSubsequent abuseYoung womenSubstance useYoung adulthoodCommunity-dwelling individualsLogistic regression analysisCurrent abusePrevious alcohol useClinical dataOpioidsDrug useSubstance abuseAlcohol useCigarettesPrevention effortsPrevious useYoung adultsYoung individualsYoung menYear olds
2007
Gender and non‐medical use of prescription opioids: results from a national US survey*
Tetrault JM, Desai RA, Becker WC, Fiellin DA, Concato J, Sullivan LE. Gender and non‐medical use of prescription opioids: results from a national US survey*. Addiction 2007, 103: 258-268. PMID: 18042194, DOI: 10.1111/j.1360-0443.2007.02056.x.Peer-Reviewed Original ResearchConceptsPast-year non-medical useNon-medical usePrescription opioidsDrug useSedative/tranquilizer useIllicit drug use disordersAlcohol abuse/dependenceDrug use disordersSerious mental illnessAbuse/dependenceIllicit drug useIllicit substance useSelf-reported alcoholGender-specific factorsCigarette smokingPrescription medicationsRisk factorsOpioidsUse disordersTranquilizer useGender-related factorsMental illnessUS residenceGreater riskSubstance use
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependence
2000
Perceptions of Benefit and Risk of Patients Undergoing First‐time Elective Percutaneous Coronary Revascularization
Holmboe E, Fiellin D, Cusanelli E, Remetz M, Krumholz H. Perceptions of Benefit and Risk of Patients Undergoing First‐time Elective Percutaneous Coronary Revascularization. Journal Of General Internal Medicine 2000, 15: 632-637. PMID: 11029677, PMCID: PMC1495592, DOI: 10.1046/j.1525-1497.2000.90823.x.Peer-Reviewed Original ResearchConceptsElective percutaneous coronary revascularizationPercutaneous coronary revascularizationMajority of patientsCoronary revascularizationAbnormal diagnostic test resultsFuture myocardial infarctionRelief of symptomsRisk of patientsDiagnostic test resultsConsecutive patientsMean ageMyocardial infarctionLong-term benefitsPossible complicationsPotential complicationsPatient decisionPatient expectationsPatientsSemistructured questionnaireRevascularizationComplicationsRiskPerceptions of benefitsPotential riskQuestionnaire